HC Wainwright Raises Tempus AI (NASDAQ:TEM) Price Target to $98.00

Tempus AI (NASDAQ:TEM) had its price target hoisted by research analysts at HC Wainwright from $90.00 to $98.00 in a research note issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price indicates a potential upside of 13.45% from the company’s previous close.

Several other research analysts have also weighed in on TEM. BTIG Research increased their target price on Tempus AI from $75.00 to $85.00 and gave the stock a “buy” rating in a research report on Wednesday, August 20th. Morgan Stanley increased their price target on Tempus AI from $65.00 to $68.00 and gave the company an “overweight” rating in a report on Tuesday, August 12th. Guggenheim increased their price target on Tempus AI from $65.00 to $75.00 and gave the company a “buy” rating in a report on Monday, June 30th. Bank of America increased their price target on Tempus AI from $68.00 to $70.00 and gave the company a “neutral” rating in a report on Wednesday, June 25th. Finally, Piper Sandler restated a “neutral” rating on shares of Tempus AI in a research note on Friday, August 8th. Seven investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $70.17.

Tempus AI Trading Down 2.7%

Shares of Tempus AI stock opened at $86.38 on Friday. The company has a quick ratio of 1.43, a current ratio of 1.54 and a debt-to-equity ratio of 2.58. The firm has a market cap of $15.01 billion, a PE ratio of -72.59 and a beta of 5.08. The business’s fifty day moving average is $67.61 and its two-hundred day moving average is $59.59. Tempus AI has a fifty-two week low of $31.36 and a fifty-two week high of $91.45.

Tempus AI (NASDAQ:TEM) last issued its earnings results on Friday, August 8th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.01. The business had revenue of $314.64 million for the quarter, compared to analyst estimates of $296.84 million. Tempus AI had a negative return on equity of 122.86% and a negative net margin of 20.98%.The business’s quarterly revenue was up 89.5% on a year-over-year basis. During the same period last year, the company posted ($6.86) EPS. Tempus AI has set its FY 2025 guidance at EPS. Analysts anticipate that Tempus AI will post -6.15 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Eric P. Lefkofsky sold 332,500 shares of Tempus AI stock in a transaction dated Wednesday, August 27th. The stock was sold at an average price of $74.10, for a total value of $24,638,250.00. Following the completion of the transaction, the chief executive officer directly owned 9,207,533 shares in the company, valued at approximately $682,278,195.30. This trade represents a 3.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Ryan Fukushima sold 17,460 shares of Tempus AI stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $74.65, for a total value of $1,303,389.00. Following the completion of the transaction, the chief operating officer owned 839,180 shares of the company’s stock, valued at $62,644,787. This trade represents a 2.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 903,104 shares of company stock valued at $63,733,330. 26.27% of the stock is owned by company insiders.

Hedge Funds Weigh In On Tempus AI

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Pathway Capital Management LP acquired a new position in Tempus AI in the first quarter valued at approximately $8,576,000. SeaCrest Wealth Management LLC bought a new stake in Tempus AI during the first quarter worth approximately $535,000. Sumitomo Mitsui Trust Group Inc. grew its position in Tempus AI by 31.4% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,255,477 shares of the company’s stock worth $205,284,000 after buying an additional 1,016,384 shares during the last quarter. Massachusetts Financial Services Co. MA grew its position in Tempus AI by 92.6% in the first quarter. Massachusetts Financial Services Co. MA now owns 578,890 shares of the company’s stock worth $27,926,000 after buying an additional 278,311 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. acquired a new position in Tempus AI in the first quarter worth approximately $1,019,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.